Litcius/Paper detail

Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B Study

Nicolas Boissel, Françoise Huguet, Thibaut Leguay, Mathilde Hunault, Rathana Kim, Yosr Hicheri, Patrice Chevallier, Marie Balsat, Sébastien Maury, Anne Thiebaut‐Bertrand, Florence Van Obbergh, Thomas Cluzeau, Martine Escoffre‐Barbe, Nicole Straetmans, Johanna Konopacki, Amine Belhabri, Alban Villate, Florence Pasquier, Ioana Vaida, Laurence Sanhès, Magda Alexis, Cédric Pastoret, Mathlide Lamarque, Laure Farnault, Nathalie Grardel, Céline Berthon, Éric Delabesse, Véronique Lhéritier, Norbert Ifrah, Carlos Graux, Yves Chalandon, Emmanuelle Clappier, Hervé Dombret

2022Blood23 citationsDOI

Abstract

International audience

Topics & Concepts

BlinatumomabLymphoblastic LeukemiaPhiladelphia chromosomeMedicineAcute lymphocytic leukemiaCancer researchInternal medicineChromosomal translocationLeukemiaImmunologyBiologyGeneticsGeneAcute Lymphoblastic Leukemia researchChronic Myeloid Leukemia TreatmentsCAR-T cell therapy research
Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B Study | Litcius